Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint

Secondary Endpoints May Matter More In FSHD Study

 
• By Alaric DeArment
  
MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Fulcrum presented data from the Phase IIb study of losmapimod in FSHD • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip